Literature DB >> 28837523

Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease.

Kaci E Christian1, Guruprasad D Jambaulikar, Matilda N Hagan, Ali M Syed, Jessica A Briscoe, Sara A Brown, Earl V Campbell, Akash B Gadani, Raymond K Cross.   

Abstract

BACKGROUND: Readmissions are being increasingly used as an indicator of quality of care. We sought to identify risk factors for 30-day readmission in hospitalized patients with inflammatory bowel disease.
METHODS: Patients with inflammatory bowel disease hospitalized between 2004 and 2013 at the University of Maryland were identified. Demographic and clinical information were extracted from the medical record for each admission. Multivariate logistic regression was performed to determine the association between these variables and readmission.
RESULTS: One thousand two hundred thirteen admissions were identified in 498 patients; 232 (19.1%) index admissions were followed by a 30-day readmission. Mean age was 39.4 ± 14.5 years. Approximately 70% of the population was white, 60% were women, and 67.5% had Crohn's disease. Concurrent congestive heart failure and chronic obstructive pulmonary disease, history of steroid use, diverting ileostomy, subtotal colectomy, or a thromboembolic event during index admission, and IV antibiotics or restricted diet at discharge were associated with readmission. After adjustment, patients with congestive heart failure or chronic obstructive pulmonary disease were more likely to be readmitted (aOR 4.06 and 2.86, respectively). Underweight or obese patients were nearly twice as likely to be readmitted (aOR 1.81 and 1.72, respectively). Those with past steroid use, new ileostomy, or those who were discharged on hyperalimentation were twice as likely to be readmitted (aOR 1.90, 2.04, and aOR 1.97, respectively).
CONCLUSIONS: Nineteen percentage of patients with inflammatory bowel disease treated at a referral center are readmitted within 30 days. Our results suggest that patients with comorbid medical conditions, malnutrition or obesity, a new ileostomy, past steroid use, or those discharged on hyperalimentation are at increased risk for readmission. Research is needed to determine if targeted interventions for high-risk patients decreases readmissions.

Entities:  

Mesh:

Year:  2017        PMID: 28837523     DOI: 10.1097/MIB.0000000000001213

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases.

Authors:  Nghia H Nguyen; Jejo Koola; Parambir S Dulai; Larry J Prokop; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-27       Impact factor: 11.382

2.  Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.

Authors:  Siddharth Singh; James Proudfoot; Ronghui Xu; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

3.  Readmission After Elective Ileostomy in Colorectal Surgery Is Predictable.

Authors:  Atif Iqbal; Ilya Sakharuk; Lindsey Goldstein; Sanda A Tan; Peihua Qiu; Zhaomian Li; Steven J Hughes
Journal:  JSLS       Date:  2018 Jul-Sep       Impact factor: 2.172

4.  The impact of obesity on hospitalized patients with ulcerative colitis.

Authors:  Mohammed El-Dallal; Daniel J Stein; Yoshihiko Raita; Joseph D Feuerstein
Journal:  Ann Gastroenterol       Date:  2021-01-27

5.  Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study.

Authors:  Mafalda Santiago; Fernando Magro; Luís Correia; Francisco Portela; Paula Ministro; Paula Lago; Eunice Trindade; Cláudia Camila Dias
Journal:  Therap Adv Gastroenterol       Date:  2020-05-20       Impact factor: 4.409

6.  Risk factors for developing high-output ileostomy in CRC patients: a retrospective study.

Authors:  Dongxiao Bai; Lei Li; Zhiling Shen; Tianchen Huang; Qingbing Wang; Yanjun Wang; Yong Zhang; Zhipeng Guo; Kan Li; Jian An Xiao
Journal:  BMC Surg       Date:  2021-06-26       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.